RedHill Biopharma

2 stories about RedHill Biopharma
גלעד רדאי

Israel’s RedHill Biopharma testing oral pill that cures Covid-19 symptoms

28.02.21|Yafit Ovadia
Israeli pharmaceutical company creates treatment to help severe and moderately-ill patients; company generates $90 million in sales annually
default image

RedHill's Public Offering Spooks Investors, Sends Stock Down

09.11.17|Dror Reich
The Nasdaq-listed biopharmaceutical company priced its shares at $5.5 per American Depositary Share, a third of its 2015 public offering price, and dropped nearly 30% by Wednesday market close